Zymeworks acquires Theravance Biopharma for US$929-million
UNVERIFIED·Primary source · The Globe and Mail
Vancouver-based Zymeworks Inc. is acquiring Theravance Biopharma Inc. for US$929-million in cash.
The deal is financed by Zymeworks' cash reserves and a US$350-million loan from OMERS.
The acquisition marks Zymeworks' entry into the respiratory illness treatment market.
Key Facts
01
01 — What / Thesis
Zymeworks acquires Theravance Biopharma for US$929-million
02
02 — Who / Subject
Zymeworks Inc., Theravance Biopharma Inc., OMERS
03
03 — Where / Locus
Canada / Ireland / USA
04
04 — When / Temporality
June 29, 2026
AI Verification Note
This article is generated by cross-referencing multiple sources and official announcements. Parts relying solely on testimony or reporting are reflected in the confidence score; content and assessment are updated as new information is confirmed.
